SPIRE – combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial

SPIRE – combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial

Abstract Background Urothelial bladder cancer (UBC) accounts for 10,000 new diagnoses and 5000 deaths annually in the UK (Cancer Research UK, http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bladder-cancer, Cancer Research UK, Accessed 26 Mar 2018). Cis...

Full description

Bibliographic Details
Main Authors: Simon Crabb, Sarah J. Danson, James W. F. Catto, Cathy McDowell, James N. Lowder, Joshua Caddy, Denise Dunkley, Jessica Rajaram, Deborah Ellis, Stephanie Hill, David Hathorn, Amy Whitehead, Mihalis Kalevras, Robert Huddart, Gareth Griffiths
Format: Article
Language:English
Published: BMC 2018-04-01
Series:Trials
Subjects:
Urothelial bladder cancer
Guadecitabine
DNA methyltransferase inhibitor
Phase I/II
Randomised controlled trial
Cisplatin resistance
Online Access:http://link.springer.com/article/10.1186/s13063-018-2586-7

Internet

http://link.springer.com/article/10.1186/s13063-018-2586-7

Similar Items